Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference

AUSTIN, Texas, Sept. 01, 2016 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today announced that its chief executive officer, David G. Lowe, Ph.D., will present at the 2016 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7 at 1:45 p.m. EDT.

The presentation will be webcast and will be available for 90 days following the live presentation. The webcast can be viewed here and on the investor relations section of the Aeglea BioTherapeutics website.

About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing recombinant human enzymes for the treatment of rare diseases and cancers associated with abnormal amino acid metabolism. The company’s recombinant human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in rare diseases or to starve tumors dependent on amino acids by reducing levels below the normal range. Aeglea’s clinical program for its lead product candidate, AEB1102, includes three recently initiated Phase 1 clinical trials, studying AEB1102 for the treatment of patients with Arginase I deficiency as well as patients with solid tumors or hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

For more information, visit http://aegleabio.com.

Media Contact: 
Kelly Boothe, Ph.D. 
BrewLife 
415.946.1076 
[email protected]

Investor Contact: 
Charles N. York II 
Chief Financial Officer
Aeglea BioTherapeutics
[email protected]